title: [Novel oral anticoagulants in patients with atrial fibrillation, how to avoid accidents?].
abstract: Know the indications of these new drugs, and respect them. Do not confuse easiness of administration and absence of precautions. Renal function: a key parameter before and during treatment. Know when to use a low-dose drug regimen. Cardioversion: lack of safety evidence for some drugs. Drug interactions: beware of P-glycoprotein and cytochrome P450.
authors: Institut Lorrain du cœur et des vaisseaux, département de cardiologie, 54511 Vandœuvre-lès-Nancy, France. Electronic address: v.manenti@chu-nancy.fr.
authors: Vladimir
authors: V
authors: Manenti
authors: Institut Lorrain du cœur et des vaisseaux, département de cardiologie, 54511 Vandœuvre-lès-Nancy, France.
authors: Etienne
authors: E
authors: Aliot
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000150:complications*; D004347:Drug Interactions; D006801:Humans; D017410:Practice Guidelines as Topic; D051437:Renal Insufficiency / Q000150:complications; D012307:Risk Factors; D013514:Surgical Procedures, Operative; D013923:Thromboembolism / Q000209:etiology* / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D014859:Warfarin